according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Doramectin Formulation**

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 28.09.2024 5198460-00017 Date of first issue: 22.10.2019 5.1

# SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Trade name : Doramectin Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub-: Veterinary product

stance/Mixture

Recommended restrictions

on use

Not applicable

1.3 Details of the supplier of the safety data sheet

Company **MSD** 

Kilsheelan

Clonmel Tipperary, IE

Telephone 353-51-601000

E-mail address of person

responsible for the SDS

: EHSDATASTEWARD@msd.com

#### 1.4 Emergency telephone number

1-908-423-6000

#### **SECTION 2: Hazards identification**

#### 2.1 Classification of the substance or mixture

#### Classification (REGULATION (EC) No 1272/2008)

Reproductive toxicity, Category 1B

H360D: May damage the unborn child.

Specific target organ toxicity - single ex-

Specific target organ toxicity - repeated

H371: May cause damage to organs.

posure, Category 2

H373: May cause damage to organs through pro-

exposure, Category 2

longed or repeated exposure.

Short-term (acute) aquatic hazard, Cate-

H400: Very toxic to aquatic life.

Long-term (chronic) aquatic hazard, Cat-

H410: Very toxic to aquatic life with long lasting

egory 1

effects.

#### 2.2 Label elements

#### Labelling (REGULATION (EC) No 1272/2008)

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Doramectin Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.07.2024

 5.1
 28.09.2024
 5198460-00017
 Date of first issue: 22.10.2019

Hazard pictograms :



¥2

Signal word : Danger

Hazard statements : H360D May damage the unborn child.

H371 May cause damage to organs.

H373 May cause damage to organs through prolonged

or repeated exposure.

H410 Very toxic to aquatic life with long lasting effects.

Precautionary statements : Prevention:

P201 Obtain special instructions before use.
P264 Wash skin thoroughly after handling.
P273 Avoid release to the environment.

P280 Wear protective gloves/ protective clothing/ eye

protection/ face protection.

Response:

P308 + P311 IF exposed or concerned: Call a POISON

CENTER/ doctor.

P391 Collect spillage.

# Hazardous components which must be listed on the label:

Doramectin

#### 2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

#### **SECTION 3: Composition/information on ingredients**

#### 3.2 Mixtures

Components

Components			
Chemical name	CAS-No.	Classification	Concentration
	EC-No.		(% w/w)
	Index-No.		
	Registration number		
Doramectin	117704-25-3	Acute Tox. 2; H300	>= 1 - < 2.5
		Repr. 1B; H360D	

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Doramectin Formulation**

ersion 1	Revision Date: 28.09.2024	SDS Number: 5198460-00017	Date of last issue: 06.07.2024 Date of first issue: 22.10.2019
			STOT SE 1; H370 (Central nervous system) STOT RE 1; H372 (Central nervous system, Liver, Kidney) Aquatic Acute 1; H400 Aquatic Chronic 1; H410
			M-Factor (Chronic aquatic toxicity): 10,000
			Acute toxicity estimate
			Acute oral toxicity: 50 mg/kg

# **SECTION 4: First aid measures**

# 4.1 Description of first aid measures

General advice : In the case of accident or if you feel unwell, seek medical ad-

vice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

Protection of first-aiders : First Aid responders should pay attention to self-protection,

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

If inhaled : If inhaled, remove to fresh air.

Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty

of water.

Remove contaminated clothing and shoes.

Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse.

In case of eye contact : Flush eyes with water as a precaution.

Get medical attention if irritation develops and persists.

If swallowed, DO NOT induce vomiting.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Doramectin Formulation**

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 28.09.2024 5198460-00017 Date of first issue: 22.10.2019 5.1

Get medical attention.

Rinse mouth thoroughly with water.

Never give anything by mouth to an unconscious person.

4.2 Most important symptoms and effects, both acute and delayed

Risks May damage the unborn child.

May cause damage to organs.

May cause damage to organs through prolonged or repeated

exposure.

4.3 Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

**SECTION 5: Firefighting measures** 

5.1 Extinguishing media

Suitable extinguishing media : Water spray

> Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

5.2 Special hazards arising from the substance or mixture

fighting

Specific hazards during fire- : Exposure to combustion products may be a hazard to health.

Hazardous combustion prod- : Carbon oxides

ucts

5.3 Advice for firefighters

Special protective equipment:

for firefighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

Evacuate area.

**SECTION 6: Accidental release measures** 

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions Use personal protective equipment.

Follow safe handling advice (see section 7) and personal pro-

tective equipment recommendations (see section 8).

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Doramectin Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.07.2024

 5.1
 28.09.2024
 5198460-00017
 Date of first issue: 22.10.2019

#### 6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.

Prevent further leakage or spillage if safe to do so.

Prevent spreading over a wide area (e.g. by containment or oil

arriers).

Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

#### 6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Soak up with inert absorbent material.

For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absor-

bent.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-

mine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

#### 6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

# **SECTION 7: Handling and storage**

#### 7.1 Precautions for safe handling

Technical measures : See Engineering measures under EXPOSURE

CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust

ventilation.

Advice on safe handling : Do not get on skin or clothing.

Do not breathe mist or vapours.

Do not swallow.

Avoid contact with eyes.

Wash skin thoroughly after handling.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as-

sessment

Keep container tightly closed.

Do not eat, drink or smoke when using this product.

Take care to prevent spills, waste and minimize release to the

environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye

flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contami-

nated clothing before re-use.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



#### **Doramectin Formulation**

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 5198460-00017 Date of first issue: 22.10.2019

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

#### 7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers

: Keep in properly labelled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national

regulations.

Advice on common storage : Do not store with the following product types:

Strong oxidizing agents

Self-reactive substances and mixtures

Organic peroxides

Explosives Gases

7.3 Specific end use(s)

Specific use(s) : No data available

#### **SECTION 8: Exposure controls/personal protection**

### 8.1 Control parameters

#### **Occupational Exposure Limits**

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis	
Doramectin	117704-25- 3	TWA	25 μg/m3 (OEB 3)	Internal	
	Further information: Skin				
		Wipe limit	250 μg/100 cm2	Internal	

#### 8.2 Exposure controls

#### **Engineering measures**

Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).

Minimize open handling.

#### Personal protective equipment

Eye/face protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



#### **Doramectin Formulation**

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 5.1 28.09.2024 5198460-00017 Date of first issue: 22.10.2019

potential for direct contact to the face with dusts, mists, or

aerosols.

Hand protection

Filter type

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Skin and body protection : Work uniform or laboratory coat.

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, dis-

posable suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially

contaminated clothing.

Respiratory protection : If adequate local exhaust ventilation is not available or expo-

sure assessment demonstrates exposures outside the rec-

ommended guidelines, use respiratory protection. Equipment should conform to I.S. EN 143

: Particulates type (P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Physical state : oily

Colour : light yellow

Odour : characteristic

Odour Threshold : No data available

Melting point/freezing point : -7 °C

Initial boiling point and boiling

range

270 °C

Flammability (solid, gas) : Not applicable

Flammability (liquids) : Not applicable

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Flash point : 215.7 °C

Auto-ignition temperature : No data available

Decomposition temperature : No data available

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Doramectin Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.07.2024

 5.1
 28.09.2024
 5198460-00017
 Date of first issue: 22.10.2019

pH : No data available

Viscosity

Viscosity, kinematic : 31.7 - 32.1 m2/s (25 °C)

Solubility(ies)

Water solubility : practically insoluble

Partition coefficient: n-

octanol/water

Not applicable

Vapour pressure : No data available

Relative density : 0.89 - 91

Density : No data available

Relative vapour density : No data available

Particle characteristics

Particle size : Not applicable

9.2 Other information

Explosives : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Evaporation rate : No data available

Molecular weight : No data available

# **SECTION 10: Stability and reactivity**

#### 10.1 Reactivity

Not classified as a reactivity hazard.

#### 10.2 Chemical stability

Stable under normal conditions.

#### 10.3 Possibility of hazardous reactions

Hazardous reactions : Can react with strong oxidizing agents.

10.4 Conditions to avoid

Conditions to avoid : None known.

10.5 Incompatible materials

Materials to avoid : Oxidizing agents

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



#### **Doramectin Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.07.2024

 5.1
 28.09.2024
 5198460-00017
 Date of first issue: 22.10.2019

#### 10.6 Hazardous decomposition products

No hazardous decomposition products are known.

#### **SECTION 11: Toxicological information**

#### 11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of : Inhalation

exposure Skin contact Ingestion

Eye contact

**Acute toxicity** 

Not classified based on available information.

**Product:** 

Acute oral toxicity : Acute toxicity estimate: > 2,000 mg/kg

Method: Calculation method

**Components:** 

**Doramectin:** 

Acute oral toxicity : LD50 (Rat): 500 mg/kg

Target Organs: Central nervous system

LD50 (Mouse): > 2,000 mg/kg

Target Organs: Central nervous system

LD50 (Rat): 50 mg/kg

Target Organs: Central nervous system

LD50 (Mouse): 75 mg/kg

Target Organs: Central nervous system

Acute toxicity (other routes of:

administration)

LD50 (Rat): > 300 mg/kg

Application Route: Intraperitoneal Target Organs: Central nervous system

#### Skin corrosion/irritation

Not classified based on available information.

#### Serious eye damage/eye irritation

Not classified based on available information.

# Respiratory or skin sensitisation

#### Skin sensitisation

Not classified based on available information.

#### Respiratory sensitisation

Not classified based on available information.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



#### **Doramectin Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.07.2024

 5.1
 28.09.2024
 5198460-00017
 Date of first issue: 22.10.2019

#### Germ cell mutagenicity

Not classified based on available information.

#### **Components:**

**Doramectin:** 

Genotoxicity in vitro : Test Type: Ames test

Result: negative

Test Type: Mouse Lymphoma

Result: negative

Test Type: unscheduled DNA synthesis assay

Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test

Species: Mouse Result: negative

Germ cell mutagenicity- As-

sessment

Weight of evidence does not support classification as a germ

cell mutagen.

#### Carcinogenicity

Not classified based on available information.

#### **Components:**

#### **Doramectin:**

Carcinogenicity - Assess-

ment

Weight of evidence does not support classification as a car-

cinogen

#### Reproductive toxicity

May damage the unborn child.

#### Components:

#### **Doramectin:**

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Rat

Application Route: Oral

Embryo-foetal toxicity: NOAEL: 0.3 mg/kg body weight

Symptoms: Reduced body weight

Test Type: Embryo-foetal development

Species: Mouse Application Route: Oral

Embryo-foetal toxicity: NOAEL: 3 mg/kg body weight

Symptoms: Embryolethal effects

Test Type: Embryo-foetal development

Species: Rabbit Application Route: Oral

General Toxicity Maternal: NOAEL: 0.75 mg/kg body weight

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



#### **Doramectin Formulation**

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 5.1 28.09.2024 5198460-00017 Date of first issue: 22.10.2019

Symptoms: Maternal effects, Embryotoxic effects.

Reproductive toxicity - As-

sessment

Clear evidence of adverse effects on development, based on

animal experiments.

#### STOT - single exposure

May cause damage to organs.

#### **Components:**

#### **Doramectin:**

Exposure routes : Oral

Target Organs : Central nervous system

Assessment : Shown to produce significant health effects in animals at con-

centrations of 300 mg/kg bw or less.

#### STOT - repeated exposure

May cause damage to organs through prolonged or repeated exposure.

#### Components:

#### **Doramectin:**

Exposure routes : Oral

Target Organs : Central nervous system, Liver, Kidney

Assessment : Shown to produce significant health effects in animals at con-

centrations of 10 mg/kg bw or less.

#### Repeated dose toxicity

#### **Components:**

# Doramectin:

Species : Rat
LOAEL : 30 mg/kg
Application Route : Oral
Exposure time : 3 Months

Target Organs : Central nervous system

Species : Rat

NOAEL : 2 mg/kg

Application Route : Oral

Exposure time : 3 Months

Target Organs : Central nervous system, Liver, Kidney

Species : Dog
NOAEL : 2 mg/kg
Application Route : Oral
Exposure time : 36 d
Target Organs : Eye

Symptoms : Dilatation of the pupil

Species : Dog

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Doramectin Formulation**

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 5.1 28.09.2024 5198460-00017 Date of first issue: 22.10.2019

NOAEL : 0.1 mg/kg Application Route : Oral Exposure time : 92 d

Target Organs : Central nervous system, Eye

Symptoms : Dilatation of the pupil

#### **Aspiration toxicity**

Not classified based on available information.

#### 11.2 Information on other hazards

#### **Endocrine disrupting properties**

#### **Product:**

Assessment : The substance/mixture does not contain components consid-

ered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at

levels of 0.1% or higher.

#### **Experience with human exposure**

#### **Components:**

**Doramectin:** 

Skin contact : Target Organs: Gastro-intestinal system

Symptoms: Nausea, Diarrhoea

Target Organs: Central nervous system Symptoms: Dizziness, Headache

Target Organs: Eye Symptoms: Irritation Target Organs: Skin Symptoms: Irritation

Target Organs: Respiratory system Symptoms: Breathing difficulties

Ingestion : Target Organs: Gastro-intestinal system

Symptoms: Nausea, Abdominal pain, Diarrhoea

Target Organs: Central nervous system

Symptoms: Dizziness

#### **SECTION 12: Ecological information**

#### 12.1 Toxicity

#### **Components:**

#### **Doramectin:**

Toxicity to fish : LC50 (Lepomis macrochirus (Bluegill sunfish)): 11 µg/l

Exposure time: 96 h

Method: OECD Test Guideline 203

LC50 (Oncorhynchus mykiss (rainbow trout)): 5.1 µg/l

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Doramectin Formulation**

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 5.1 28.09.2024 5198460-00017 Date of first issue: 22.10.2019

Exposure time: 96 h

Method: OECD Test Guideline 203

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 0.1 μg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

M-Factor (Chronic aquatic

toxicity)

10,000

**Ecotoxicology Assessment** 

Acute aquatic toxicity : Very toxic to aquatic life.

12.2 Persistence and degradability

No data available

12.3 Bioaccumulative potential

**Components:** 

**Doramectin:** 

Bioaccumulation : Species: Lepomis macrochirus (Bluegill sunfish)

Bioconcentration factor (BCF): 71 Method: OECD Test Guideline 305

Partition coefficient: n-

octanol/water

log Pow: 4.5

pH: 7

12.4 Mobility in soil

**Components:** 

**Doramectin:** 

Distribution among environ-

mental compartments

: log Koc: 4.94

12.5 Results of PBT and vPvB assessment

**Product:** 

Assessment : This substance/mixture contains no components considered

to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of

0.1% or higher.

**Components:** 

**Doramectin:** 

Assessment : Substance is not very persistent and very bioaccumulative

(vPvB).

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Doramectin Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.07.2024

 5.1
 28.09.2024
 5198460-00017
 Date of first issue: 22.10.2019

#### 12.6 Endocrine disrupting properties

**Product:** 

Assessment : The substance/mixture does not contain components consid-

ered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at

levels of 0.1% or higher.

#### 12.7 Other adverse effects

No data available

#### **SECTION 13: Disposal considerations**

#### 13.1 Waste treatment methods

Product : Dispose of in accordance with local regulations.

According to the European Waste Catalogue, Waste Codes

are not product specific, but application specific.

Waste codes should be assigned by the user, preferably in

discussion with the waste disposal authorities.

Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste han-

dling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

#### **SECTION 14: Transport information**

#### 14.1 UN number or ID number

ADN : UN 3082
ADR : UN 3082
RID : UN 3082
IMDG : UN 3082
IATA : UN 3082

14.2 UN proper shipping name

**ADN** : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,

N.O.S.

(Doramectin)

**ADR** : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,

N.O.S.

(Doramectin)

RID : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,

N.O.S.

(Doramectin)

IMDG : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,

N.O.S.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



#### **Doramectin Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.07.2024

 5.1
 28.09.2024
 5198460-00017
 Date of first issue: 22.10.2019

(Doramectin)

IATA : Environmentally hazardous substance, liquid, n.o.s.

(Doramectin)

14.3 Transport hazard class(es)

Class Subsidiary risks

ADN : 9
ADR : 9
RID : 9
IMDG : 9
IATA : 9

14.4 Packing group

ADN

Packing group : III
Classification Code : M6
Hazard Identification Number : 90
Labels : 9

**ADR** 

Packing group : III
Classification Code : M6
Hazard Identification Number : 90
Labels : 9
Tunnel restriction code : (-)

RID

Packing group : III
Classification Code : M6
Hazard Identification Number : 90
Labels : 9

**IMDG** 

Packing group : III
Labels : 9
EmS Code : F-A, S-F

IATA (Cargo)

Packing instruction (cargo : 964

aircraft)

Packing instruction (LQ) : Y964
Packing group : III

Labels : Miscellaneous

IATA (Passenger)

Packing instruction (passen: 964

ger aircraft)

Packing instruction (LQ) : Y964
Packing group : III

Labels : Miscellaneous

14.5 Environmental hazards

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



#### **Doramectin Formulation**

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 5.1 28.09.2024 5198460-00017 Date of first issue: 22.10.2019

**ADN** 

Environmentally hazardous : yes

**ADR** 

Environmentally hazardous : yes

**RID** 

Environmentally hazardous : yes

IMDG

Marine pollutant : yes

IATA (Passenger)

Environmentally hazardous : yes

IATA (Cargo)

Environmentally hazardous : yes

#### 14.6 Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

#### 14.7 Maritime transport in bulk according to IMO instruments

Remarks : Not applicable for product as supplied.

#### **SECTION 15: Regulatory information**

# 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles (Annex XVII) Conditions of restriction for the following entries should be considered: Number on list 3

Substance(s) or mixture(s) are listed here according to their appearance in the regulation, irrespective of their use/purpose or the conditions of the restriction. Please refer to the conditions in corresponding Regulation to determine whether an entry is applicable to the placing on the market or

not. Not applicable

REACH - Candidate List of Substances of Very High

Concern for Authorisation (Article 59).

Regulation (EC) on substances that deplete the ozone

layer

Regulation (EU) 2019/1021 on persistent organic pollu-

tants (recast)

Regulation (EU) No 649/2012 of the European Parliament and the Council concerning the export and import of dangerous chemicals

: Not applicable

Not applicable

Not applicable

Not applicable

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Doramectin Formulation**

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 5198460-00017 Date of first issue: 22.10.2019

REACH - List of substances subject to authorisation : Not applicable

(Annex XIV)

Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of

major-accident hazards involving dangerous substances.

Quantity 1 Quantity 2

E1 ENVIRONMENTAL 100 t 200 t

**HAZARDS** 

#### Other regulations:

Take note of Directive 92/85/EEC regarding maternity protection or stricter national regulations, where applicable.

Take note of Directive 94/33/EC on the protection of young people at work or stricter national regulations, where applicable.

#### The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

#### 15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

#### **SECTION 16: Other information**

Other information : Items where changes have been made to the previous version

are highlighted in the body of this document by two vertical

lines.

#### **Full text of H-Statements**

H300 : Fatal if swallowed.

H360D : May damage the unborn child.

H370 : Causes damage to organs if swallowed.

H372 : Causes damage to organs through prolonged or repeated

exposure if swallowed.

H400 : Very toxic to aquatic life.

H410 : Very toxic to aquatic life with long lasting effects.

#### Full text of other abbreviations

Acute Tox. : Acute toxicity

Aquatic Acute : Short-term (acute) aquatic hazard
Aquatic Chronic : Long-term (chronic) aquatic hazard

Repr. : Reproductive toxicity

STOT RE : Specific target organ toxicity - repeated exposure STOT SE : Specific target organ toxicity - single exposure

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regula-

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Doramectin Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.07.2024

 5.1
 28.09.2024
 5198460-00017
 Date of first issue: 22.10.2019

tion (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA -European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of Very High Concern; TCSI - Taiwan Chemical Substance Inventory; TECI -Thailand Existing Chemicals Inventory; TRGS - Technical Rule for Hazardous Substances; TSCA - Toxic Substances Control Act (United States); UN - United Nations; vPvB - Very Persistent and Very Bioaccumulative

#### **Further information**

Repr. 1B STOT SE 2

STOT RE 2

Aquatic Acute 1

Sources of key data used to compile the Safety Data Sheet

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, http://echa.europa.eu/

#### Classification of the mixture:

# Calculation method Calculation method Calculation method Calculation method

Calculation method

Classification procedure:

Aquatic Chronic 1 H410

H360D

H371

H373

H400

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Doramectin Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.07.2024

 5.1
 28.09.2024
 5198460-00017
 Date of first issue: 22.10.2019

IE / EN